Our R01 grant is funded by the NIH/NCI

Published by sahinozgur on

Our R01 grant aiming at blocking tumor growth and metastasis in highly aggressive breast cancers has been funded. In this exciting project, we will target highly aggressive breast cancers with our newly developed inhibitor.

Categories: Grant

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *

Related Posts

Grant

Our new R01 grant is funded by the NIH/NCI

This 5-year grant will address the mechanisms of resistance to chemotherapy in highly aggressive breast cancers using cutting-edge methodologies, including testing our recently developed LOX inhibitors. NEW positions are available for highly motivated postdocs and Read more…

Grant

Dr. Sahin receives highly prestigious Mary Kay Ash Foundation grant

This work aims to enhance the efficacy of antibody-drug conjugate (ADC) therapy in aggressive breast cancer. Here is the press release: https://marykayashfoundation.org/what-we-do/cancer-research/grant-recipients/

Announcement

Dr. Sahin receives the prestigious American Cancer Society Research Scholar Grant (ACS-RSG)

Dr. Sahin received the prestigious American Cancer Society Research Scholar Grant. The grant, totaling nearly $800,000 over the next four years, will support our research on overcoming tamoxifen resistance and blocking metastasis in breast cancer. Read more…